Karen Anderson
Professor,
School of Life Sciences
Other ASU affiliations
Biodesign Center for Personalized Diagnostics
Health Solutions Ambassador,
College of Health Solutions
-
Phone: 480-965-6982
-
-
Biodesign A220A 1001 S. McAllister Ave Tempe, AZ 85281
-
Mail code: 6401Campus: Tempe
-
Long Bio
Dr. Karen Anderson is a tumor biologist who studies how the immune system can be harnessed to detect and alter cancer development. For example, cancer causes the body to produce specific antibodies, which she and her research team can use as biomarkers to detect cancer in early stages of its growth. They use the alterations in immune response to develop new biomarkers for breast, ovarian, pancreatic and HPV-related cancers.
Dr. Anderson and her collaborators use molecular techniques, such as in vitro protein arrays, next-gen sequencing, and high-throughput functional genomics, to study early alterations in cancer development. They examine the abnormal characteristics of cancer to identify novel targets for cancer treatment and vaccine development.
Education
- Ph.D. Department of Microbiology and Immunology Duke University, Durham NC
- M.D. Duke University School of Medicine Medical Scientist Training Program
- B.A. Department of Chemistry University of Virginia, Charlottesville, VA
Google Scholar URL
Research Interests
The Anderson laboratory is focused on understanding how the immune response can be used to detect and alter cancer development. To create an effective cancer immunotherapy, Dr. Anderson’s team identifies target antigens for vaccine development, and understanding of the mechanisms of immune regulation that limit effective immunotherapy. The lab uses proteomic tools to perform immunoprofiling for cancer and infectious disease detection and monitoring.
Research Group
Publications
- Anderson KS, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, Qiu J, Vitonis A, LaBaer J. Autoantibody signature for the serologic detection of ovarian cancer. Journal Proteome Research. 2015 Jan 2;14(1):578-86 doi: 10.1021/pr500908n. Epub 2014 Nov 17. PMID 25365139; PMCID: PMC4334299
- Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease, Cancer Epidemiol Biomarkers Prev.2015 Feb;24(2):435-41. doi: 10.1158/1055-9965.EPI-14-1178. Epub 2014 Dec 3. PMID: 25471344 PMCID: PMC4323938
- Chowell D, Castillo-Chavez C, Krishna S, Qiu X, Anderson KS. Modelling the effect of early detection of Ebola. Lancet Infect Dis. 2015 Feb;15(2):148-49. doi: 10.1016/S1473-3099(14)71084-9. Epub 2015 Jan 19. PMID: 25749063
- Chowell D, Krishna S, Becker PD, Cocita, C, Shu J, Tan X, Greenberg PD, Klavinskis LS, Blattman JN, Anderson KS. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1754-62.doi: 10.1073/pnas.1500973112. Epub 2015 Mar 23. PMID: 25831525; PMCID: PMC4394253
- Anderson KS, Dahlstrom KR, Cheng JN, Alam R, Li G, Wei Q, Gross ND, Chowell D, Posner M, Sturgis EM. HPV 16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncol. 2015 Jul;51(7):662-7. doi: 10.1016/j.oraloncology.2015.04.011. Epub 2015 May 6. PMID: 25957822; PMCID: PMC4457560
- Dahlstrom KR, Anderson KS, Cheng JN, Chowell D, Li G, Posner M, Sturgis EM. HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. Clin Cancer Res. 2015 Jun 15;21(12):2861-9, doi: 10.1158/1078-0432.CCR-14-3323. PMID: 26078432
- Anderson KS, Gerber JE, D’Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncol. 2015 Aug;51(8):751-8. doi: 10.1016/j.oraloncology.2015.05.007. Epub 2015 Jun 18. PMID: 26094591
- Barrett MT, Anderson KS, Lenkiewicz E, Andreozzii M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 2015 Sep 22;6(28):26483-93. doi: 10.18632/oncotarget.4494 PMID: 26317899
- Ewaisha R, Meshay I, Resnik J, Katchman BA, and Anderson KS. Programmable protein arrays for immunoprofiling HPV-associated cancers, Proteomics. 2016 Apr;16(8):1215-24. doi: 10.1002/pmic.201500376. Epub 2016 Apr 7. PMID: 27089055
- Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. Proteomics Clin Appl. 2016 Jul;10(7):720-31. doi: 10.1002/prca.201500096. Epub 2016 May 17. PMID: 27121307
- Katchman BA, Smith JT, Obahiagbon U, Kesiraju S, Lee YK, O’Brien B, Kaftanoglu K, Blain Christen J, Anderson KS. Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers. Sci Rep. 2016 Jul 4;6:29057. doi: 10.1038/srep29057. PMID: 27374875
- Dahlstrom KR, Anderson KS, Sturgis EM. Human Papillomavirus-Associated Oropharyngeal Cancer: Not Just White Men Anymore. JAMA Oncol. 2016 Dec 8. doi:10.1001/jamaoncol.2016.3510 PMID: 27930755
- Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, Anderson KS. Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol. 2017 Apr 17. Pii: S0090-8258(17)30775-8 doi: 10.1016/j.yfyno.2017.04.005. PMID: 28427776
- Anderson KS, Wallstrom G, Langseth H, Posner M, Cheng JN, Alam R, Chowell D, Furre IE, Mork J. Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. Oral Oncology 2017 Oct. 2017 Sep 1. PMID: 28939065
- Chen M, Andreozzi M, Pockaj B, Barrett MT, Ocal IT, McCullough AE, Linnaus ME, Chang JM, Yearley JH, Annamalai L, Anderson KS. Development and Validation of a Novel Clinical Fluorescence in Situ Hybridization Assay to Detect JAK2 and PD-L1 amplification. Modern Pathology. 2017 Nov;30(11):1516-1526.PMID: 28752839
- Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the Evolutionary and Ecological Features of Neoplasms. Nature Reviews Cancer. 2017 Oct;17(10):605-619. PMID: 28912577
- Ewaisha R, Panicker G, Maranian P, Unger R, Anderson KS. Serum Immune Profiling for Early Detection of Cervical Disease. Theranostics. 2017 Aug 23;7(16):3814-3823. PMID: 29109779
- Chowell D, Napier J, Gupta R, Anderson KS, Maley CC, Wilson Sayres MA. Modeling the subclonal evolution of cancer cell populations. Cancer Res. 2017 Nov 29. PMID: 29187407
- Dahlstrom KR, Anderson KS, Field MS, Chowell D, Ning J, Li N, Wei Q,Li G, Sturgis EM. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. Cancer. 2017 Dec 15;123(24):4886-4894. PMID: 28898394
- Anderson KS. Mork J, Langseth H, Wallstrom G. Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodologic issues. Oral Oncol. 2018 May. PMID: 29606498.
- Kaaks R, Fortner RT, Hüsing A, Barrdahl M, Hopper M, Johnson T, Tjønneland A, Hansen L, Overvad K, Fournier A, Boutron-Ruault MC, Kvaskoff M, Dossus L, Johansson M, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Sieri S, Mattiello A, Palli D, Tumino R, Matullo G, Onland-Moret NC, Gram IT, Weiderpass E, Sánchez MJ, Navarro Sanchez C, Duell EJ, Ardanaz E, Larranaga N, Lundin E, Idahl A, Jirström K, Nodin B, Travis RC, Riboli E, Merritt M, Aune D, Terry K, Cramer DW, Anderson KS. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. Int J Cancer, 2018 Feb 22. PMID: 29473162
- Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. Krishna S, Ulrich P, Wilson E, Parikh F, Narang P, Yang S, Read AK, Kim-Schulze S, Park JG, Posner M, Wilson Sayres MA, Sikora A, Anderson KS. Cancer Res. 2018 Nov 1;78(21):6159-6170. PMID:30154146
- Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers. Katchman BA, Zhu M, Blain Christen J, Anderson KS. Proteomics Clin Appl. 2018 Nov;12(6):e1800010. PMID: 29882373
- The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. MT Barrett, Elizabeth Lenkiewicz, Smriti Malasi, Anamika Basu, Jennifer Holmes Yearley, Lakshmanan Annamalai, Ann E. McCullough, Heidi E. Kosiorek, Pooja Narang, Melissa A. Wilson Sayres, Meixuan Chen, Karen S. Anderson & Barbara A. Pockaj. Breast Cancer Research 2018; 20 (1), 1-15
- Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, Niu R, Anderson KS. JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer. Clin Breast Cancer. 2018 Oct;18(5):e1205-e1215. Erratum in: Clin Breast Cancer. 2019 Feb;19(1):87-88.PMID:29933930
- Henderson MC, Silver MS, Tran Q, Letsios E, Mulpuri R, Reese DE, Lourenco AP, LaBaer J, Anderson KS, Hollingsworth A, Alpers J, Costantini C, Peterson H, Rohatgi N, Haythem A, Baker K, Northfelt D, Ghosh K, Grobmyer S, Polen W, Wolf J. A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Post-Menopausal Women with BI-RADS 3, 4, or 5 Assessment. Clin Cancer Res. 2019 Jan 1;25(1):142-149. PMID:30185421
- Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin SF, Farooq M, Mejia R, Cronin PA, Anderson KS, Kosiorek HE, Northfelt DW, McCullough AE, Patel BK, Weitzel JN, Slavin TP, Caldas C, Pockaj BA, Murtaza M. Sci Transl Med. 2019 Aug 7;11(504). PMID: 31391323
- The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study. Campos-Romero A, Anderson KS, Longatto-Filho A, Luna-Ruiz Esparza MA, Morán-Portela DJ, Castro-Menéndez JA, Moreno-Camacho JL, Calva-Espinosa DY, Acosta-Alfaro MA, Meynard-Mejía FA, Muñoz-Gaitán M, Alcántar-Fernández J. Sci Rep. 2019 Jul 12;9(1):10094. PMID: 31300693
- Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Ferdosi SR, Ewaisha R, Moghadam F, Krishna S, Park JG, Ebrahimkhani MR, Kiani S, Anderson KS. Nat Commun. 2019 Apr 23;10(1):1842. PMID:31015529
- The neoepitope landscape of breast cancer: implications for immunotherapy. Narang P, Chen M, Sharma AA, Anderson KS, Wilson MA. BMC Cancer. 2019 Mar 4;19(1):200. PMID:30832597
- Autoantibodies in Early Detection of Breast Cancer. Rauf F, Anderson KS, LaBaer J.Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2475-2485.
- Biomarkers and Strategies for Early Detection of Ovarian Cancer. Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Skates SJ.Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2504-2512.
- Total predicted MHC-I epitope load is inversely associated with mortality from SARS-CoV-2. Wilson EA, Hirniese G, Singharoy A, and Anderson KS. 2021, Cell Reports Medicine.
- The Public Health Impact of Delaying a Second Dose of the BNT162b2 or mRNA-1273 COVID-19 Vaccine. Romero-Brufau S, Chopra A, Ryu AJ, Gel E, Raskar R, Kremers W, Anderson KS, Subramanian J, Krishnamurthy B, Abhishek S, Pasupathy K, Dong Y, O’Horo JC, Wilson WR, Mitchell O, Kingsley TC. British Medical Journal. 2021; British Med J.
Research Activity
- Anderson,Karen S*, Blattman,Joseph Nathan, Yan,Hao. Single Cell Technologies for Rapid Detection of Tumor Heterogeneity. HHS-NIH-NCI(9/1/2015 - 7/31/2018).
- Anderson,Karen S*. Conditionally Reprogrammed Cells as a New Tool for Biobanking. GEORGETOWN UNIV(8/31/2015 - 8/31/2016).
- Blain Christen,Jennifer Mary*, Anderson,Karen S. SCH: INT: Disposable High Sensitivity Point of Care Immunosensors for Multiple Disease and Pathogen Detection. NSF-CISE-IIS(8/1/2015 - 7/31/2019).
- Anderson,Karen S*. Detection of HPV16 Serology in Head and Neck Cancer. (4/10/2015 - 8/31/2015).
- Anderson,Karen S*, Borges,Chad Randolph. Targeting Breast Cancer Tumor Antigens for Immunotherapy. BCRF(3/1/2015 - 2/29/2016).
- Anderson,Karen S*, Blattman,Joseph Nathan, Yan,Hao. Single Cell Analysis of Breast Cancer Tumor Heterogeneity. ASU-Mayo Seed Grant(1/1/2015 - 12/31/2015).
- Mangone,Marco*, Anderson,Karen S. Detection and validation of miRNA targets in breast cancer. HHS-NIH-NCI(9/12/2014 - 8/31/2016).
- Anderson,Karen S*. Validation of Biomarkers of Risk for the Early Detection of Lung Cancer. Vanderbilt(7/1/2014 - 6/30/2016).
- Anderson,Karen S*. Rapid disease diagnostics using photonic crystal enhanced antigen biomarker microarrays. UNIV OF ILLINOIS - CHAMP/URBAN(6/1/2014 - 5/31/2019).
- Anderson,Karen S*. Establishment of Conditionally Reprogrammed Breast Cell Lines. MAYO CLINIC SCOTTSDALE(3/10/2014 - 3/9/2015).
- Anderson,Karen S*. Photonic Crystal Enhanced Fluorescence: Development of Sensor Structures and Detection Instrumentation for Multiplexed Biomarker Detection. UNIV OF ILLINOIS - CHAMP/URBAN(9/17/2013 - 8/31/2015).
- Davies,Paul*, Anderson,Karen S, Davies,Pauline A, Lindsay,Stuart, Lindsay,Stuart, Meldrum,Deirdre Ruth, Ros,Robert. YR 5: Beyond Center - A Center for the Convergence of Physical Science and Cancer Biology. HHS-NIH-NCI(9/1/2013 - 8/31/2015).
- Anderson,Karen S*. Conditionally Reprogrammed Cells as a New Tool for Biobanking. GEORGETOWN UNIV(9/1/2013 - 8/31/2014).
- Davies,Paul*, Davies,Paul*, Anderson,Karen S, Davies,Pauline A, Lindsay,Stuart, Lindsay,Stuart, Meldrum,Deirdre Ruth, Ros,Robert. YR 4: Beyond Center - A Center for the Convergence of Physical Science and Cancer Biology. HHS-NIH-NCI(9/1/2012 - 8/31/2013).
- Anderson,Karen S*, Labaer,Joshua, Wallstrom,Garrick L. Mutation-Specific p53 Antibodies as Biomarkers of Pancreatic Cancer. HHS-NIH-NCI(8/8/2012 - 7/31/2014).
- Labaer,Joshua*, Anderson,Karen S, Qiu,Ji, Wallstrom,Garrick L, Wallstrom,Garrick L. Biomarker Detection Using NAPPA Tumor Antigen Arrays. HHS-NIH-NCI(8/1/2010 - 6/30/2016).
Courses
2024 Fall
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| MIC 492 | Honors Directed Study |
| MIC 495 | Undergraduate Research |
| BDE 792 | Research |
| BIO 495 | Undergraduate Research |
| CHM 392 | Intro to Research Techniques |
2024 Summer
| Course Number | Course Title |
|---|---|
| BDE 792 | Research |
2024 Spring
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| BIO 493 | Honors Thesis |
| MBB 493 | Honors Thesis |
| MIC 493 | Honors Thesis |
| MBB 495 | Undergraduate Research |
| BIO 495 | Undergraduate Research |
| BDE 799 | Dissertation |
| BDE 792 | Research |
| BDE 795 | Continuing Registration |
| BDE 799 | Dissertation |
2023 Fall
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| MIC 492 | Honors Directed Study |
| MIC 495 | Undergraduate Research |
| BDE 792 | Research |
| BIO 495 | Undergraduate Research |
2023 Summer
| Course Number | Course Title |
|---|---|
| BDE 792 | Research |
2023 Spring
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| BIO 493 | Honors Thesis |
| MBB 493 | Honors Thesis |
| MIC 493 | Honors Thesis |
| MBB 495 | Undergraduate Research |
| BIO 495 | Undergraduate Research |
| BDE 799 | Dissertation |
| BDE 792 | Research |
| BDE 795 | Continuing Registration |
| BDE 799 | Dissertation |
2022 Fall
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| MIC 492 | Honors Directed Study |
| MIC 495 | Undergraduate Research |
| BDE 792 | Research |
| BIO 495 | Undergraduate Research |
2022 Summer
| Course Number | Course Title |
|---|---|
| BDE 792 | Research |
2022 Spring
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| BIO 493 | Honors Thesis |
| MBB 493 | Honors Thesis |
| MIC 493 | Honors Thesis |
| MBB 495 | Undergraduate Research |
| BIO 495 | Undergraduate Research |
| BDE 799 | Dissertation |
| BDE 792 | Research |
| BDE 792 | Research |
| BDE 795 | Continuing Registration |
| BDE 799 | Dissertation |
2021 Fall
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| MIC 492 | Honors Directed Study |
| BDE 792 | Research |
| BIO 495 | Undergraduate Research |
2021 Summer
| Course Number | Course Title |
|---|---|
| BDE 792 | Research |
2021 Spring
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| BIO 493 | Honors Thesis |
| MBB 493 | Honors Thesis |
| MIC 493 | Honors Thesis |
| MBB 495 | Undergraduate Research |
| BIO 495 | Undergraduate Research |
| BDE 799 | Dissertation |
| BDE 792 | Research |
2020 Fall
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| MIC 492 | Honors Directed Study |
| BDE 792 | Research |
| BIO 495 | Undergraduate Research |
2020 Summer
| Course Number | Course Title |
|---|---|
| BDE 792 | Research |
2020 Spring
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| BIO 493 | Honors Thesis |
| MBB 493 | Honors Thesis |
| MIC 493 | Honors Thesis |
| MBB 495 | Undergraduate Research |
| BIO 495 | Undergraduate Research |
| BDE 799 | Dissertation |
| BDE 792 | Research |
2019 Fall
| Course Number | Course Title |
|---|---|
| BIO 492 | Honors Directed Study |
| MIC 492 | Honors Directed Study |
| MIC 493 | Honors Thesis |
| BDE 792 | Research |
2019 Summer
| Course Number | Course Title |
|---|---|
| BDE 792 | Research |
Presentations
- Karen Anderson, M.D., Ph.D. "Programmable protein microarrays for cancer biomarker detection.". UC Riverside Environmental Toxicology Program (Nov 2014).
- Karen Anderson, M.D., Ph.D. "Molecular Biomarkers for the Early Detection of Cancer". The Third Annual Global Biomarkers Consortium, San Francisco, CA (Oct 2014).
- Karen Anderson, M.D., Ph.D. "Proteomics for Early Detection of Cancer". Lankenau Institute, Philadelphia, PA (Sep 2014).
- Karen Anderson, M.D., Ph.D. "Designing Pipelines for Breast Cancer Biomarker Discovery and Validation.". NCI W.W.- Japan Joint Workshop on Biomarkers for Early Cancer Detection, Bethesda, MD (Feb 2014).
- Karen Anderson, M.D., Ph.D. "Modeling immune regulation of tumor dormancy". NCI Mathmatical Models of Breast Cancer Worksop (Jan 2014).
- Karen Anderson. Immunotherapy of Breast Cancer: Using Proteomics for Immune Monitoring. Lecture Series - Mayo Clinic Rochester, MN (Aug 2012).
- Karen Anderson. Mapping the immunome: Using proteomics for cancer detection and prognosis". MCB 701 (Jan 2012).
Honors / Awards
Health Care Heroes Award, Phoenix Business Journal
Most Influential Women in Arizona, Arizona Business Magazine
Professional Associations
American Association for Cancer Research American Society of Clinical Oncology
Service
- Faculty Search Committee, SoLS-Biomarkers, Member (2014 - Present)
- Womanity 2014 Panel, Presenter, Panel/Presenter (2014 - Present)
- Mayo Clinic, Educational Lectures, Speaker (2014 - Present)
- TGen Breast Cancer Retreat, Speaker (2014 - Present)
- ASU Foundation’s Women & Philanthropy Program, "Detecting Cancer: From Bench to Bedside", Presenter (2013 - Present)
- Basis Chandler High School, biomarkers to detect cancer at early stages, vaccine development and cancer treatment, guest speaker, (2013 - Present)
- AZ Science Center - Framing New Pathways to Medical Discovery for Families, Students, and Teachers. New Frontiers in Medical Science, Presentation (2013 - Present)
- Horizon (PBS) Invited Interview, Collaboration - Making a Difference in Medical Research and Public Health, Interview (2013 - Present)
- City of Phoenix Women's Commision, Panel (2013 - Present)
- Executive Committee for the AZ Biomarker Alliance, Member (2012 - Present)
- Mayo Clinic Cancer Center in Arizona Research Committee, Member (2012 - Present)
- College of Reviewers, Genome Canada, Large Scale Applied Research Project Competition, Member (2012 - Present)
- Genome Canada, Large Scale Research Projects Review Committee, Member (2012 - Present)
- Komen IIR PED & IIR/CCR METIR Peer Review Committee, Member (2012 - Present)
- NCI Physical Sciences of Oncology, Center Advisory Committee, Member (2012 - Present)
- Cancer Biomarkers Study Section, Center for Scientific Review, Member (2012 - 2016)
- NCI Cancer Bioamarkers Study Section Committee, Ad-hoc (2011 - 2016)
- NCI Cancer Biomarkers Study Section Committee, Standing member (2012 - 2016)
- DNASU Faculty/Scientific Advisory Committee, SoLS, Member (2014 - 2016)
- Komen IIR PEd & IIR/CCR Metir Peer Review Committee, Member (2014 - 2014)
- NCI AIDS associated Opportunistic Infections (AOIC) Review Committee, Ad hoc member (2014 - 2014)
- NCI Detection of Pathogen associated Cancer committee, Ad hoc committee member (2014 - 2014)
- Mayo Clinic Cancer Center in Arizona Research Committee, Member (2014 - 2014)
- Platform Technologies Challenge, Keck Foundation, Reviewer (2013 - 2014)
- Facilities Committee, Member (2012 - 2013)
- Faculty Search Committee, School of Life Sciences, Member (2012 - 2013)
- Women In Stem, Workshop Lean In, Panelist (2013 - 2013)
- Komen IIR PEd & IIR/CCR Metir Peer Review Committee, Member (2012 - 2013)
- ASU-NIH Day, Best Practice for WRiting Proposals for NIH, Panelist (2013 - 2013)
- ASU Faculty Women's Assocation, Panelist (2012 - 2012)
- NCI Cancer Bioamarkers Study Section Committee, Ad-hoc (2011 - 2012)
- Breast Cancer Interest Group, Member (2011 - 2012)
- MCB Graduate School Admissions Committee, Member (2011 - 2012)